4//SEC Filing
Gengos Andrew 4
Accession 0001563623-26-000002
CIK 0001831363other
Filed
Jan 15, 7:00 PM ET
Accepted
Jan 16, 5:23 PM ET
Size
8.0 KB
Accession
0001563623-26-000002
Insider Transaction Report
Form 4
Gengos Andrew
Chief Financial Officer
Transactions
- Award
Common Stock
[F1][F2]2026-01-14+68,750→ 101,788 total - Award
Stock Option (Right to Buy)
[F3]2026-01-14+137,500→ 137,500 totalExercise: $37.18Exp: 2036-01-13→ Common Stock (137,500 underlying)
Footnotes (3)
- [F1]Each share is represented by a Restricted Stock Unit ("RSU"). 25% of the RSUs vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/16th of the total number of shares vest quarterly thereafter, such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date.
- [F2]Includes 8,038 shares acquired by the Reporting Person under the Issuer's 2021 Employee Stock Purchase Plan ("ESPP") on November 30, 2025.
- [F3]25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.
Signature
/s/ David Strauss, as Attorney-in-Fact for Andrew Gengos|2026-01-16
Documents
Issuer
Terns Pharmaceuticals, Inc.
CIK 0001831363
Entity typeother
Related Parties
1- filerCIK 0001563623
Filing Metadata
- Form type
- 4
- Filed
- Jan 15, 7:00 PM ET
- Accepted
- Jan 16, 5:23 PM ET
- Size
- 8.0 KB